Open access

Aspirin Therapy Resistance in Coronary Artery Bypass Grafting

Written By

Inna Kammerer

Submitted: 20 June 2012 Published: 13 March 2013

DOI: 10.5772/54414

From the Edited Volume

Artery Bypass

Edited by Wilbert S. Aronow

Chapter metrics overview

1,755 Chapter Downloads

View Full Metrics

1. Introduction

The success of coronary artery bypass grafting (CABG) surgery mainly depends on the patency of graft vessels. The predominant mechanism of early graft failure after coronary surgery is associated with antiplatelet treatment using drungs such as acetylsalicylic acid (ASA). Prevention using oral ASA in the early postoperative phase in patients with vascular disease is associated with a 25% to 44% reduction in adverse cardiovascular events (1; 2). Daily ASA doses ranging between 75-1200mg can similarly reduce fatal and nonfatal events (2; 3), although studies directly comparing lower and higher doses with regard to clinical outcomes in the CABG setting have been lacking [4].


2. Clinical ASA resistance

The antithrombotic effect of ASA has been primarily attributed to the irreversible blockade of the cyclooxygenase- 1 (COX-1) enzyme in platelets that leads to attenuation in the production of an important platelet agonist, thromboxane A2 TXA2 (1; 2). ASA irreversibly inhibits cycloxygenase-1 by acetylating a serine residue at position 529, thereby preventing the conversion of arachidonic acid to unstable prostaglandine intermediate PGH2, which is converted to thromboxane TxA2, a potent vasoconstrictor and platelet agonist [22]. The finding that a considerable number of patients show an impaired antiplatelet effect of ASA in CAD patients, eminently after CABG threw new light into the discussion concerning poor patency rates of bypass grafts: the early period after CABG shows a coincidence of an increased risk for bypass thrombosis (amongst others, due to platelet activation and endothelial cell disruption of the graft) and an increased prevalence of ASA resistance [5]. In recent years, an increasing number of reports about ASA resistance have led to a growing concern among clinicians and patients about the efficacy of ASA treatment (6; 7; 8; 9), although one study group could not reveal any ASA resistance after CABG [10]. ASA resistance can be defined clinically as an ischemic event while on ASA therapy. Various studies have evaluated the antiplatelet effect of ASA therapy and have reported the prevalence of ASA resistance 0.4% - 35% of cardiovascular [11, 18] and 5 - 65% of stroke patients [19, 20].

ASA failure has been attributed to many causes, including insufficient dosage, reduced absorption or increased metabolism, diabetes mellitus, genes polymorphisms, cell-cell and drug-drug interactions and poor compliance [12]. Recent findings have suggested that the pyrazolinone analgesic metamizol, ibuprofen and other nonsteroidal analgesic anti-inflammatory drugs, but not diclofenac, may prevent the irreversible inhibition of platelet thromboxane formation by ASA [15]. The variation suggests about many more treatment failures with ASA therapy (including incompliance of patients) can be explained by a reduced antiplatelet effect for pharmacological reasons Table 1.

Drug-related ASA / Clopidogrel resistance
• Incompliance (23)
• Pharmacokinetics / Pharmacodynamics
• Insufficient bioavailability (low dose-effect relationship)
• Prevention of binding to the Ser529 by other NSAID (Ibuprofen, Indomethacin, Naproxen)
• Exogenous toxins (diabetes mellitus, smoking)
• Impaired sensitivity of platelet COX-1 (CABG)
• Gene polymorphism(s) (COX-1, COX-2, Thromboxan-A2-synthase, Glycoprotein Ia / IIb-, -Ib / V / IX and IIb / IIIa receptor, Collagen, v.-Willebrand factor and factor VIII)
• Alternative metabolism of thromboxan-A2-biosynthesis (ASA resistance)
• Changing of enteral resoption and biotransformation (Clopidogrel resistance)
Disease-related ASA / Clopidogrel resistance
• Platelet hyperreactivity due to ASA-insensitive mechanisms
• Changes in the collagen receptor
• Platelet “sensitizing” by Isoprostanes

Table 1.

Mechanisms of ASA / Clopidogrel resistance


3. ASA response tests

The common using tests platelet function analyzer (PFA-100TM) closure times (CT); turbidimetric platelet aggregation (TPA) and impedance platelet aggregation (IPA) depending of platelet and leukocyte counts, Hb, fibrinogen and von Willebrand factor collagen binding assay (VWF:CBA), the best valid laboratory procedure was not been determinate to screen for ASA or clopidogrel resistance. One of the studies on on-pump CABG patients agrees with previous findings suggesting that different platelet function assays that are suitable for detecting ASA resistance can not be used interchangeably. Simple linear regression analysis revealed significant association among CEPI-CT, AA TPA and AA IPA and collagen IPA Table 2 [14]. In the majority of cases AA IPA (impedance platelet aggregation induced by arachidonic acid) [16, 17] and ADP-induced platelet aggregation [4] were utilized.

AATPA Collagen AAIPA Collagen
CEPI-CT r=0,49* NS r=0,35 r=0,31
p<0,0001 p<0,0001 p=0001
AATPA r=0,38* r=0,43* r=0,28
p<0,0001 p<0,0001 p=0,0006
Collagen TPA NS r=0,22
AAIPA r=0,52

Table 2.

Linear regression analysis (Spearman rank correlation coefficients, levels of significance (P<0.01)) determined in 42 CABG patients before, 1h and 24 h after 300 mg of aspirin intravenously (n=126)

*confirmed by multiple regression analysis

CEPI-CT, collagen/epinephrine closure times; TPA, turbidimetric platelet aggregation; AATPA, turbidimetric platelet aggregation induced by arachidonic acid; collagen TPA, turbidimetric platelet aggregation induced by collagen; IPA, impedance platelet aggregation; AAIPA, impedance platelet aggregation induced by arachidonic acid; collagen IPA, impedance platelet aggregation induced by collagen.

The clean comparison between both different procedures of CABG: on- and off-pump surgery is unperformed, the role of using extracorporeal circulation as potential destroyer of cell components for ASA Response uncertain. ASA resistence is a transient phenomenon during the early postoperatively period in approximately 30% of OPCAB patients, whereby the ASA response was revered by 6 months [16, 17].

The new age antiplatelet therapy with clopidogrel, prasugrel or ticagrelor seems be effective in most cardiology diseases (Platelet Inhibition and Patient Outcomes = PLATO Study) like acute coronary syndrome (ACS), unstable angina pectoris, myocardial infarction (non-STEMI or STEMI) with non- and invasive procedures [13], however is not standard medication for patients after CABG procedure like ASA. Clopidogrel (75mg/day) is a prodrug, which needs to be metabolized in the liver to active metabolites catalysed by Cytochrom-P450-Oxygenase CYP 3A4 and 3A5, which irreversibly inactivate the platelet ADP receptor P2Y12. Different to ASA clopidogrel does to influent the thienopyridins not cyclooxygenase and thromboxan formation. Platelet inhibition in patients group with response to clopidogrel was enhanced by switching to ticagrelol therapy and all clopidogrel. A few studies have revealed important individual heterogeneity in platelet response to clopidogrel in patients with stable coronary disease, but the clinical significance of this phenomenon has not yet been investigated. Matetzky showed in his study that in 15 out of 60 consecutive patients STEMI (25%) were resistant to clopidogrel and subsequently were at increased risk of recurrent cardiovascular events in a 6-month follow-up [24].

Non-Responders and Responders treated with ticagrelor will have platelet reactivity below the cut points associated with ischemic risk in the RESPOND Study [4]. Their resistance in cardiac surgery after using of extracorporeal circulation (on-pump) or without (off pump) is unidentified.

Regarding the PLATO trials (Platelet Inhibition and Patient Outcome by ticagrelol) underwent CABG endpoints were a non-significant reduction of the primary endpoint like total major bleeding [HR: 0.84 (95% CI = 0.60–1.16), p = 0.29], significant reduction of CV death [HR: 0.52 (95% CI = 0.32–0.85)] and all-cause death [HR: 0.49 (95%CI = 0.32– 0.77)] [13]. CABG-related major bleedings according to PLATO or TIMI bleeding definitions were observed very commonly during CABG.


4. Conclusion

Antiplatelet therapy with ASA is the cornerstone of treatment in coronary artery disease patients especiallity after CABG surgery. The question of ASA resistence can be defined clinically as an ischaemic even while on ASA treatment daily. Laboratory assays of ASA response are surrogate measures as platelet aggregation inhibitor in vitro does not coincidentally translate into prevention of thrombosis in vivo, however the tests are not comparibale among themself. Clinical studies are needed to discover the optimal dosing and the clinical significance of laboratory aspirin resistance for sufficiency of graft function.



CABG=coronary artery bypass grafting, ASA=acetylsalicylic acid, CAD = coronary artery disease,mg=milligram, COX-1=cyclooxygenase-1, OPCAB=off-pump coronary artery bypass, TXA2 = thromboxane A2, STEMI=ST segment elevation myocardial infarction


  1. 1. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. 2004 Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest; 126: 234–64
  2. 2. Antithrombotic Trialists’ Collaboration. 2002 Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 324:71– 86
  3. 3. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schröder K, Hohlfeld T. 2001 Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg; 212:982–4
  4. 4. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US 2007 Evaluation of dose-related effects of Aspirin on platelet function: results from the Aspirin-induced platelet effect (ASPECT) Study Circulation; 115;3156-64
  5. 5. Stein PD, Schunemann HJ, Dalen JE, Gutterman D. 2004 Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: The seventh ACCP conference on Antithrombotic and Thrombolytic therapy Chest; 126(Suppl 3):600-8S
  6. 6. Golanski J, Chlopicki S, Golan´ ski R, Gresner P, Iwaszkiewicz, A, Watala C. 2005 Resistance to aspirin in patients after coronary artery bypass graftings is transient. Ther Drug Monit;27 :484–90
  7. 7. Yilmaz MB, Balbay Y, Caldir V, Ayez S, Guray Y, Guray U, Korkmaz S. 2005 Late saphenous vein graft occlusion in patients with coronary bypass: Possible role of aspirin resistance. Thromb Res;115: 25–9
  8. 8. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schröder K, Hohlfeld T. 2001 Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg; 212:982–4
  9. 9. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schröder K, Hohlfeld T. 2003 Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation;108: 542–7
  10. 10. Mengistu AM, Wolf MW, Boldt J, Röhm KD, Lang J, Piper SN. 2008 Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. J Cardiothorac Vasc Anesth.; 22 (1):40-6
  11. 11. Cox D, Maree AO, Dooley R, Byrne MF, Fitzgerald DJ. 2006 Effect of enteritic coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke; 37: 3153–58
  12. 12. Tantry US, Bliden KP, Gurbel PA. 2005 Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother.;6: 2027–45
  13. 13. Giannitsis E, Katus HA Antiplatelet therapy - ticagrelor. Hamostaseologie. 2012 Jun 28;32(3)
  14. 14. Kammerer I, Bach J, Saggau W, Isgro F. Functional evaluation of platelet aspirin resistance after on-pump coronary bypass grafting using multiple aggregation tests. Thorac Cardiovasc Surg. 2011 Oct;59(7):425-9
  15. 15. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573–4
  16. 16. Wang Z, Gao F, Men J, Ren J, Modi P, Wei M Aspirin resistance in off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2012 Jan;41(1):108-12
  17. 17. Kempfert J, Anger K, Rastan A, Krabbes S, Lehmann S, Garbade J, Sauer M, Walther T, Dhein S, Mohr FW Postoperative development of aspirin resistance following coronary artery bypass. Eur J Clin Invest. 2009 Sep; 39(9):769-74
  18. 18. Schrör K, Hohlfeld T, Weber AA Aspirin resistance - does it clinically matter? Clin Res Cardiol. 2006 Oct;95(10):505-10
  19. 19. Mason PJ, Jacobs AK, Freedman JE (2005) Aspirin resistence and atherothrombotic disease. J Am Coll Cardiol 46:986-93
  20. 20. Hennekens CH, Schrör K, Weisman S, Fitz GA (2004) Terms and Conditions. Semantic complexicity and aspirin resistence. Circulation 110:1706-8
  21. 21. Mani H., E. Lindhoff-Last Resistenz gegen Azetylsalizylsäure und Clopidogrel Hämostaseologie 2006 26 3: 229-238
  22. 22. Mani H, Linnemann B, Luxembourg B, Kirchmayr K, Lindhoff-Last E Response to aspirin and clopidogrel monitored with different platelet function methods Platelets. 2006 Aug;17(5):303-10
  23. 23. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, Vered Z, Krakover R, Kaluski E, Kornberg A Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004 Feb;147(2):293-300.
  24. 24. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation. 2004 Jun 29;109(25):3171-5

Written By

Inna Kammerer

Submitted: 20 June 2012 Published: 13 March 2013